MWG Biotech to divest genomic diagnosis:
This article was originally published in Clinica
Executive Summary
Ebersberg, Germany-based MWG Biotech has decided to distance itself from certain non-core business lines, including genomic diagnosis. Board member Wolfgang Pieken said the company was confident of finding new partners for the businesses to be divested. They "contain highly innovative and recognised product and service portfolios", he said. MWG's genomic diagnosis business makes DNA microarrays for use in research. Its Genomic Technology business, focused on laboratory automation, will also be divested. The company will focus on gene sequencing and genomic synthesis.